Abstract
Cancer cachexia, defined by the gradual depletion of muscle and fat mass, is a complex multifactorial syndrome affecting up to 80% of cancer patients. This study investigated the effects of Curcuma xanthorrhiza extract (CXE) and xanthorrhizol (XAN) in ameliorating cancer-induced muscle atrophy in BALB/c mice. Treatment with CXE and XAN reversed muscle mass loss, grip strength decline, and decrease in myofiber size induced by cancer. In gastrocnemius muscle tissue, CXE and XAN downregulated the expression of nuclear factor kappa-beta (NF-κB), reducing the expression levels of proinflammatory cytokines. They also suppressed catabolic factors, including myostatin and ubiquitin-proteasome E3 ligases, and the nuclear translocation of forkhead box O3a. Furthermore, CXE and XAN promoted skeletal muscle anabolism by stimulating myogenesis and activating the phosphoinositide 3-kinase/protein kinase B signaling pathway. This activation subsequently upregulated the mammalian target of rapamycin and its downstream molecules. Overall, CXE and XAN effectively mitigated skeletal muscle catabolism induced by cancer cachexia and may serve as an intervention for inhibiting muscle atrophy in affected cancer patients if efficacy can be confirmed in human trials.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
